Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound Axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that Axitinib extended progression-free survival (PFS) when compared to sorafenib, in the study population.
Subscribe to our email newsletter
Pfizer said that Axitinib is an oral and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3.
Pfizer Oncology Business Unit Clinical Development senior vice president Mace Rothenberg said that it is gratifying that in this trial Axitinib provided significant benefit to patients with advanced RCC whose disease had progressed after 1st-line therapy.
"These results provide insight into the potential value of Axitinib as part of a sequential treatment approach in patients with advanced RCC, Rothenberg said.
"We will work with health authorities to determine possible filing options for Axitinib for use in patients with advanced RCC."